Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Total Non-Current Liabilities: 2015-2024

Historic Total Non-Current Liabilities for Syndax Pharmaceuticals (SNDX) over the last 10 years, with Dec 2024 value amounting to $333.1 million.

  • Syndax Pharmaceuticals' Total Non-Current Liabilities rose 16108650.00% to $322.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $322.2 million, marking a year-over-year increase of 16108650.00%. This contributed to the annual value of $333.1 million for FY2024, which is 56556.97% up from last year.
  • Latest data reveals that Syndax Pharmaceuticals reported Total Non-Current Liabilities of $333.1 million as of FY2024, which was up 56,556.97% from $588,000 recorded in FY2023.
  • Over the past 5 years, Syndax Pharmaceuticals' Total Non-Current Liabilities peaked at $333.1 million during FY2024, and registered a low of $588,000 during FY2023.
  • For the 3-year period, Syndax Pharmaceuticals' Total Non-Current Liabilities averaged around $111.5 million, with its median value being $722,000 (2022).
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first crashed by 96.50% in 2022, then skyrocketed by 56,556.97% in 2024.
  • Syndax Pharmaceuticals' Total Non-Current Liabilities (Yearly) stood at $29.6 million in 2020, then crashed by 30.27% to $20.6 million in 2021, then slumped by 96.50% to $722,000 in 2022, then decreased by 18.56% to $588,000 in 2023, then spiked by 56,556.97% to $333.1 million in 2024.